As­traZeneca cuts PhI­II tri­al short af­ter next-gen check­point drug fails in­ter­im analy­sis

Four years af­ter promis­ing ear­ly da­ta in head and neck can­cer drew As­traZeneca to a big-mon­ey deal with In­nate Phar­ma around its next-gen­er­a­tion check­point in­hibitor, the com­pa­nies are grap­pling with dis­ap­point­ing Phase III re­sults.

As­traZeneca is ax­ing the Phase III IN­TER­LINK-1 study af­ter mon­al­izum­ab flunked a fu­til­i­ty in­ter­im analy­sis, In­nate re­port­ed. Its shares on Nas­daq $IPHA fell more than 16% to $2.57 in pre-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER